Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

634
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
634
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

678
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
678
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

430
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
430
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

628
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
628
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

550
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
550
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response by Fonarow et al to Letter Regarding Article, "Improving Heart Failure Quality of are Over the First Twenty Years: The Get With The Guidelines-Heart Failure Program".

Circulation. Heart failure·2026
Same author

Fast Image Segmentation Toward Automation of 3D Ice Printing.

Chemical & biomedical imaging·2026
Same author

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same author

Sisyphean Task of Cardiovascular Prevention: Real Gains, Unequal Progress.

Circulation·2026
Same author

Rural-Urban Disparity in Postacute Care and 1-Year Outcomes After Ischemic Stroke.

Stroke·2026
Same author

In-Hospital Stroke Quality and Outcomes in the Mechanical Thrombectomy Era: Get With The Guidelines-Stroke, 2016 to 2023.

Stroke·2026

Related Experiment Video

Updated: Feb 23, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Changes in parameters of right ventricular function with cardiac resynchronization therapy.

Abhishek Sharma1,2, Carl J Lavie3, Ajay Vallakati4

  • 1Division of Cardiovascular Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York.

Clinical Cardiology
|September 13, 2017
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy (CRT) improves right ventricle (RV) function in heart failure patients. However, these improvements are dependent on patient-specific factors like age and QRS duration, not independent of baseline variables.

Keywords:
cardiac resynchronization therapyright ventricular function

More Related Videos

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

4.8K
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

11.2K

Related Experiment Videos

Last Updated: Feb 23, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

4.8K
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

11.2K

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Cardiac resynchronization therapy (CRT) is used to treat heart failure (HF).
  • Previous studies indicated CRT improves right ventricle (RV) size and function in HF patients.
  • The impact of CRT on RV function independent of baseline clinical variables requires further investigation.

Purpose of the Study:

  • To evaluate the effectiveness of CRT on RV function.
  • To determine if RV function improvements with CRT are independent of baseline clinical variables.

Main Methods:

  • Systematic literature search of studies from 1966 to August 2015.
  • Included studies reporting RV function parameters (TAPSE, FAC, strain, diameters) before and after CRT.
  • Performed meta-analysis and meta-regression to assess CRT's impact and its independence from covariates (age, QRS duration, LVEF).

Main Results:

  • Analyzed 13 studies with 1541 patients.
  • CRT showed significant improvements in TAPSE, RV FAC, basal strain, and RV dimensions.
  • Meta-regression revealed that improvements in RV function were dependent on age, QRS duration, and baseline LVEF.

Conclusions:

  • CRT significantly improves various echocardiographic parameters of RV function.
  • These improvements are not independent of baseline clinical variables.
  • RV function enhancement with CRT is statistically linked to patient age, QRS duration, and baseline LVEF.